Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib
Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib
复制标题
流式细胞术分析作为伊马替尼治疗慢性期慢性粒细胞白血病儿童治疗反应的额外预测工具
DOI：
10.1002/pbc.26478
复制
发表时间：
2017
影响因子：
3.2
通讯作者：
Ad
中科院分区：
文献类型：
--
作者：
Shima Haruko;Kiyokawa Nobutaka;Miharu Masashi;Tanizawa Akihiko;Kurosawa Hidemitsu;Watanabe Akihiro;Ito Masaki;Tono Chikako;Yuza Yuki;Muramatsu Hideki;Hotta Noriko;Okada Masahiko;Hamamoto Kazuko;Kajiwara Ryosuke;Saito Akiko M;Horibe Keizo;Mizutani Shuki;Ad
在诊断时和伊马替尼治疗开始后获得新诊断的慢性期慢性髓细胞白血病（CML）儿童的骨髓样本，并使用抗人CD 34、CD 38、CD 123、CD 45 RA、cMpl和谱系抗体进行染色。流式细胞术分析显示，诊断时粒细胞巨噬细胞祖细胞在CML祖细胞中占优势，3个月时骨髓祖细胞中cMpl表达升高，可能预测伊马替尼治疗慢性期CML儿童的不良结局。我们建议在治疗早期进行骨髓流式细胞术分析，因为它是一种方便的工具，可以预测治疗反应并指导CML管理。
Bone marrow samples of newly diagnosed children with chronic‐phase chronic myeloid leukemia (CML) were obtained at diagnosis and after imatinib initiation and stained with anti‐human CD34, CD38, CD123, CD45RA, cMpl, and lineage antibodies. Flow cytometric analysis revealed that granulocyte macrophage progenitor predominance in CML progenitors at diagnosis and elevated cMpl expression in bone marrow progenitors at 3 months may predict poor outcome in children with chronic‐phase CML treated with imatinib. We recommend flow cytometric analysis of bone marrow in the early phase of treatment, as it is a convenient tool that may predict treatment response and guide CML management.